Phase I study of vorinostat (suberoylanilide hydroxamic acid) in combination with temozolomide (TMZ) in patients with malignant gliomas (NABTC 04-03)

被引：0
|
作者：
Wen, P. Y.
Puduvalli, V.
Kuhn, J.
Reid, J.
Cloughesy, T.
Yung, W. A.
Chang, S. M.
Robbins, H. I.
McGovern, R.
Ames, M.
Prados, M. D.
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] UT Southwestern, San Antonio, TX USA
[4] Mayo Clin, Rochester, MN USA
[5] Univ Calif Los Angeles, Med Ctr, Los Angeles, CA 90024 USA
[6] Univ Calif San Francisco, San Francisco, CA 94143 USA
[7] Univ Wisconsin, Madison, WI USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2039
引用
收藏
页数：2
相关论文
共 50 条
  • [41] A phase I study of temozolomide and lapatinib combination in patients with recurrent high-grade gliomas
    Vasilios Karavasilis
    Vassiliki Kotoula
    George Pentheroudakis
    Despina Televantou
    Sofia Lambaki
    Sofia Chrisafi
    Mattheos Bobos
    George Fountzilas
    Journal of Neurology, 2013, 260 : 1469 - 1480
  • [42] PHASE I STUDY OF VORINOSTAT COMBINED WITH ISOTRETINOIN AND CARBOPLATIN IN ADULTS WITH RECURRENT MALIGNANT GLIOMAS
    Puduvalli, Vinay K.
    Penas-Prado, Marta
    Gilbert, Mark R.
    Groves, Morris D.
    Hess, Kenneth R.
    Levin, Victor A.
    de Groot, John
    Colman, Howard
    Conrad, Charles A.
    Loghin, Monica E.
    Hunter, Kathy
    Yung, W. K.
    NEURO-ONCOLOGY, 2010, 12 : 69 - 69
  • [43] Vorinostat (suberoylanilide hydroxamic acid) as salvage therapy in metastatic breast cancer (MBC): A California Cancer Consortium phase II study
    Luu, T. H.
    Leong, L.
    Morgan, R.
    McNamara, M.
    Lim, D.
    Portnow, J.
    Frankel, P.
    Aparicio, A.
    Chew, H.
    Gandara, D. R.
    Somlo, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [44] Translational Phase I Trial of Vorinostat (Suberoylanilide Hydroxamic Acid) Combined with Cytarabine and Etoposide in Patients with Relapsed, Refractory, or High-Risk Acute Myeloid Leukemia
    Gojo, Ivana
    Tan, Ming
    Fang, Hong-Bin
    Sadowska, Mariola
    Lapidus, Rena
    Baer, Maria R.
    Carrier, France
    Beumer, Jan H.
    Anyang, Bean N.
    Srivastava, Rakesh K.
    Espinoza-Delgado, Igor
    Ross, Douglas D.
    CLINICAL CANCER RESEARCH, 2013, 19 (07) : 1838 - 1851
  • [45] Phase I study of oral suberoylanilide hydroxamic acid (SAHA) in patients (pts) with advanced leukemias or myelodysplastic syndromes (MDS).
    Garcia-Manero, G
    Canalli, AA
    Wierda, W
    Cortes, J
    O'Brien, S
    Cupo, A
    Secrist, JP
    Davis, J
    Faderl, S
    Giles, F
    Chiao, JH
    Richon, V
    Issa, JP
    Kantarjian, H
    BLOOD, 2003, 102 (11) : 254B - 254B
  • [46] A phase I study of bortezomib (BTZ) and temozolomide (TMZ) in patients with advanced solid tumors
    Portnow, J.
    Koehler, S.
    Cristea, M. C.
    Chow, W. A.
    Chung, V. M.
    Lim, D.
    Morgan, R.
    Shibata, S.
    Frankel, P. H.
    Synold, T. W.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [47] Phase I/II study of imatinib mesylate (STI571) for patients with recurrent malignant gliomas (NABTC 99-08)
    Wen, PY
    Yung, WKA
    Lamborn, K
    Peng, B
    Dahia, P
    Abrey, L
    Raiser, J
    Cloughesy, T
    Fink, K
    Gilbert, M
    Chang, S
    Junck, L
    Schiff, D
    Lieberman, F
    Fine, H
    Mehta, M
    Robins, HI
    DeAngelis, LM
    Hess, K
    Groves, M
    Puduvalli, VK
    Levin, V
    Conrad, C
    Kuhn, J
    Maher, E
    Hayes, M
    Silberman, S
    Letvak, L
    Capdeville, R
    Kaplan, R
    Murgo, A
    Stiles, C
    Prados, MD
    NEURO-ONCOLOGY, 2004, 6 (04) : 385 - 385
  • [48] A phase II trial of arsenic trioxide and temozolomide in combination with radiation therapy for patients with malignant gliomas
    Kumthekar, Priya
    Grimm, Sean
    Chandler, James
    Mehta, Minesh
    Marymont, Maryanne
    Levy, Robert
    Muro, Kenji
    Helenowski, Irene
    McCarthy, Katie
    Fountas, Leanne
    Raizer, Jeffrey
    JOURNAL OF NEURO-ONCOLOGY, 2017, 133 (03) : 589 - 594
  • [49] A phase II trial of arsenic trioxide and temozolomide in combination with radiation therapy for patients with malignant gliomas
    Priya Kumthekar
    Sean Grimm
    James Chandler
    Minesh Mehta
    Maryanne Marymont
    Robert Levy
    Kenji Muro
    Irene Helenowski
    Katie McCarthy
    Leanne Fountas
    Jeffrey Raizer
    Journal of Neuro-Oncology, 2017, 133 : 589 - 594
  • [50] Phase I study of low-dose metronomic temozolomide for recurrent malignant gliomas
    Eric T. Wong
    Joshua Timmons
    Amy Callahan
    Lauren O’Loughlin
    Bridget Giarusso
    David C. Alsop
    BMC Cancer, 16
12345